Robert Berger, MD
About
Appointments
Psychiatry
Clinical InstructorPrimary
Other Departments & Organizations
Education & Training
- MD
- New York University School of Medicine (1976)
Research
Publications
2024
A Prostatic Intraepithelial Neoplasia-Dependent p27Kip1 Checkpoint Induces Senescence and Inhibits Cell Proliferation and Cancer Progression
Majumder P, Grisanzio C, O'Connell F, Barry M, Brito J, Xu Q, Guney I, Berger R, Herman P, Bikoff R, Fedele G, Baek W, Wang S, Ellwood-Yen K, Wu H, Sawyers C, Signoretti S, Hahn W, Loda M, Sellers W. A Prostatic Intraepithelial Neoplasia-Dependent p27Kip1 Checkpoint Induces Senescence and Inhibits Cell Proliferation and Cancer Progression. Cancer Cell 2024, 42: 1126. PMID: 38866454, DOI: 10.1016/j.ccell.2024.05.008.Peer-Reviewed Original ResearchAvelumab + axitinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC): Final overall survival (OS) analysis from the JAVELIN Renal 101 phase 3 trial.
Motzer R, Penkov K, Uemura H, Campbell M, Kollmannsberger C, Lee J, Venugopal B, Van Den Eertwegh A, Negrier S, Gurney H, Albiges L, Berger R, Haanen J, Rini B, Larkin J, Schmidinger M, Sandner R, Wang J, Di Pietro A, CHOUEIRI T. Avelumab + axitinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC): Final overall survival (OS) analysis from the JAVELIN Renal 101 phase 3 trial. Journal Of Clinical Oncology 2024, 42: 4508-4508. DOI: 10.1200/jco.2024.42.16_suppl.4508.Peer-Reviewed Original ResearchCitationsConceptsAdvanced renal cell carcinomaPD-L1+ tumorsProgression-free survivalOverall survivalJAVELIN RenalPD-L1Sunitinib armSafety profileFollow-upUntreated advanced renal cell carcinomaImmune checkpoint inhibitorsPD-(L)1 inhibitorsOverall populationSecond-line therapyMedian follow-upFirst-line treatmentPhase 3 trialRenal cell carcinomaInhibitor combination treatmentLong-term efficacySP263 assayCheckpoint inhibitorsPD-(L)1Data cutoffSecond-linePhase 1 study of AM003, a novel individualized immunotherapy, in a basket of advanced solid tumors.
Amitzi L, Lavi E, Hanin N, Pode Z, Berger R, Smith K. Phase 1 study of AM003, a novel individualized immunotherapy, in a basket of advanced solid tumors. Journal Of Clinical Oncology 2024, 42: tps2692-tps2692. DOI: 10.1200/jco.2024.42.16_suppl.tps2692.Peer-Reviewed Original ResearchConceptsSolid tumorsIndividualized immunotherapyClinical benefitTumor cellsFirst-in-human phase 1Preliminary evidence of clinical benefitEvidence of clinical benefitImmune-oncology agentsDose-escalation partAdvanced solid tumorsDose-escalation studyRelapsed/refractory solid tumorsAdvanced/metastatic solid tumorsTumor cell lysisPatient tumor cellsPhase 1 studyImmune T cellsAntigen presenting cellsFirst-in-humanStimulate antigen presenting cellsIdentification of biomarkersCTCAE v5Dose expansionIT injectionSystemic therapy
2022
1129 A novel CpG motif introduced into a bispecifc AM003 compound for the treatment of solid tumors
Hanin N, Lavi E, Pode Z, Dahan S, Buravenkov V, Carasso L, Bachelet I, Berger R, Levy I. 1129 A novel CpG motif introduced into a bispecifc AM003 compound for the treatment of solid tumors. 2022, a1173-a1173. DOI: 10.1136/jitc-2022-sitc2022.1129.Peer-Reviewed Original Research